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The majority of risk factors for chronic inﬂammatory diseases are unknown. This makes
personalized medicine for assessment, prognosis, and choice of therapy very difﬁcult.
It is becoming increasingly clear, however, that low-grade subclinical infections may be
an underlying cause of many chronic inﬂammatory diseases and thus may contribute to
secondary outcomes (e.g., cancer). Many diseases are now categorized as inﬂammatory-
mediated diseases that stem from a dysregulation in host immunity. There is a growing
need to study the links between low-grade infections, the immune responses they elicit,
and how this impacts overall health. One such link explored in detail here is the extreme
sensitivity of myeloid dendritic cells (mDCs) in peripheral blood to chronic low-grade
infections and the role that thesemDCs play in arbitrating the resulting immune responses.
We ﬁnd that emerging evidence supports a role for pathogen-induced mDCs in chronic
inﬂammation leading to increased risk of secondary clinical disease. The mDCs that are
elevated in the blood as a result of low-grade bacteremia often do not trigger a productive
immune response, but can disseminate the pathogen throughout the host. This aberrant
trafﬁcking ofmDCs can accelerate systemic inﬂammatory disease progression. Conversely,
restoration of dendritic cell homeostasis may aid in pathogen elimination and minimize
dissemination. Thus it would seem prudent when assessing chronic inﬂammatory disease
risk to consider bloodmDCnumbers, and themicrobial content (microbiome) and activation
state of these mDCs.These may provide important clues (“the canary in the coal mine”) of
high inﬂammatory disease risk. This will facilitate development of novel immunotherapies
to eliminate such smoldering infections in atherosclerosis, cancer, rheumatoid arthritis, and
pre-eclampsia.
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INTRODUCTION TO BLOOD DENDRITIC CELLS
Tissue dendritic cells (DCs) are the peripheral sentinels of the
human immune system (Banchereau and Steinman, 1998). As
such, they play a seminal role in alerting the immune system
so that a vigorous immune response can be mounted against
a pathogen. This is balanced against the need of DCs to mit-
igate inappropriate responses toward commensal microbes or
self-antigens (Banchereau et al., 2000). Circulating blood DCs
are unique from tissue DCs in that they lack dendrites and
do not express maturation markers such as CD83 (Ziegler-
Heitbrock et al., 2010). They are identiﬁed by lack of Lin- (lineage)
speciﬁc markers such as CD3, CD14, CD19, CD56, and gly-
cophorin A and can be separated based on phenotype and
function into three types: plasmacytoid DCs (pDCs) and two
types of conventional or myeloid DCs (mDCs; Dzionek et al.,
2000; Ziegler-Heitbrock et al., 2010; Hemont et al., 2013). pDCs,
derived from lymphoid progenitors, are identiﬁed by the expres-
sion of CD123, CD303, and CD304. pDCs strongly express
Toll-like receptor (TLR)-7 and -9, producing type-I interferons
(IFNs) in response to CpGs but not lipopolysaccharide (LPS;
Colonna et al., 2004; Gilliet et al., 2008). pDCs predominantly
recognize viral antigens and are natural IFN producers (Colonna
et al., 2004; Gilliet et al., 2008). mDCs are highly phagocytic,
antigen-processing DCs that recognize both bacterial and viral
antigens (Steinman and Inaba, 1999; MacDonald et al., 2002).
The two subsets of mDCs are CD1c+ (BDCA-1+) mDCs and
rare CD141+ mDCs. CD1c+ mDCs express all TLR except TLR-
9, while CD141+ mDCs express a more restricted pattern with
high expression of TLR-3 and -10, expression of TLR-1, -2,
-6, and -8, and lack of TLR-4, -5, -7, and -9. The major
response of CD141(+) mDCs to TLR-3 ligand and their cytokine
production pattern suggest a role for these cells in antiviral immu-
nity (Hemont et al., 2013). For this review, we will focus on
mDCs.
mDCs are generated from common myeloid progenitors
and are crucial in recognizing various pathogens, migrating
through the lymph stream to secondary lymphoid organs (SLOs;
Antonysamy et al., 1999) where they stimulate adaptive immu-
nity and generate distinct CD4 effector T helper responses
(Sallusto et al., 1998; Steinman and Inaba, 1999). Due to
their great migratory capabilities and weak bactericidal mech-
anisms, mDCs in blood may be particularly susceptible to
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exploitation by pathogens, which this review will discuss in some
detail.
TYPICAL PHYSIOLOGICAL DEVELOPMENT OF BLOOD DC
Dendritic cells predominantly function within the conﬁnes of the
tissues, lymphatics, and SLOs (Antonysamy et al., 1999). Blood
mDCs are rare and comprise a very small population of total
circulating leukocytes; usually below 1% of the total numbers.
Circulating progenitors are typically divided into conventional
DCs, which have archetypal DC functions and phenotype, as
well as pre-DCs. The pre-DCs can be further developed into DC
subtypes: HLA-DR+CD11c+ or HLA-DR+CD123+ (Pulendran
et al., 2000). While very low in abundance in blood, mDCs are
widely distributed in the body and can drive immune activation
or tolerance, depending on state of activation or maturation, as
we discuss later in this review. Additionally, mDCs exhibit typi-
cally short lifespans, especially after activation, and need constant
replenishing. The inﬂuence of ﬂuctuation of blood mDC number
on host immune responses and homeostasis is unclear. What is
clear is that mDCs are relatively rare in the blood, and rapidly
mobilize in response to factors such as the DC-poietin Flt-3 lig-
and, and thus may be essential to normal physiology (Jefford et al.,
2003; Karsunky et al., 2003). The hematopoiesis and generation
of mDCs is complicated by the numerous subtypes of mDCs as
well as the differences in steady state or inﬂammatory develop-
ment (Shortman and Naik, 2007). The mDC system is generally
in a state of constant ﬂux, but this is intensiﬁed during infection
and inﬂammation.
DIFFERENTIATION OF mDCs FROM MONOCYTES
Blood monocytes are progenitors of mDCs with the ability to
differentiate into various myeloid lineage cell types (Zhou and
Tedder, 1996; Auffray et al., 2009). In vitro blood monocytes can
be induced to differentiate into immature monocyte-derived DCs
(MoDCs), by adding granulocyte macrophage colony-stimulating
factor (GM-CSF) and interleukin (IL)-4 (Xu et al., 1995; Kiertscher
and Roth, 1996; Palucka et al., 1998). MoDCs display very sim-
ilar phenotype and functions as typical blood mDCs (Chapuis
et al., 1997; Leon and Ardavin, 2008). Due to the low abundance
of blood mDCs, this culturing technique has been essential for
elucidating the functions of DCs. MoDCs (León et al., 2005)
have been used to study the role of various stress conditions
such as graft vs. host rejection (Antonysamy et al., 1999; Lutz
et al., 2000), TLR stimulation (Krutzik et al., 2005), and autoim-
munity (Blanco et al., 2001) and cancer (Thurner et al., 1999;
Kiertscher et al., 2000; Schuler-Thurner et al., 2002; Figdor et al.,
2004).
Myeloid precursors such as monocytes can rapidly differen-
tiate into distinct populations of mDCs not typically present
during steady state conditions, when encountering microbial
and inﬂammatory signals. These signals can elicit rapid and
sustained elevations of mDCs; such as occur during chronic,
low-grade infections. This is typically discussed in the con-
text of infection of peripheral tissues, which results in inﬂux
of CCR2+ blood monocytes to the site, where inﬂammatory
stimuli promote differentiation of monocytes into mDCs (Geiss-
mann et al., 2003, 2010; Cheong et al., 2010). TLR stimulation
of monocytes appears to be essential for rapid differentiation
of two distinct populations of MoDCs: DC-SIGN+CD16+ and
CD1b/c+DC-SIGN− (Krutzik et al., 2005). Additionally, recent
work by our group demonstrates that low grade intracellu-
lar infection of monocytes stimulates their rapid differentiation
into CD1c+DC-SIGN+ MoDCs (Miles et al., 2013a). Depending
on the signals, however, these increases do not always corre-
late with productive immune responses, as the resultant mDC
pool can often be immuno-incompetent. Hence, an increase in
mDCs during chronic infections may further exacerbate inﬂam-
matory diseases through faulty pathogen elimination and antigen
presentation. Therefore, it becomes extremely important to quan-
titate and characterize the activation state of mDCs that are
mobilized in the blood in response to low-grade infections.
These observations might have potential in a clinical setting, as
both a way to predict disease risk and as a targeted therapy
approach.
TRANSMIGRATION OF mDCs TO AND FROM TISSUES
Upon antigen acquisition, DCs undergo a maturation process
characterized by downregulation of their phagocytic machinery
and upregulation of their antigen presenting capacity. The cos-
timulatory (and coinhibitory) molecules on DCs that alter antigen
presentation by DCs are discussed below. The process of DC
maturation occurs simultaneously with an upregulation of the
chemokine receptor CCR7 (Forster et al., 2008), which directs
mature DCs to different lymphoid compartments where a gradi-
ent of CCL19/21 is present (Randolph et al., 2008). The functions
of speciﬁc chemokine receptors on DCs and their ligands have
been previously reviewed (Mohit and Rafati, 2012) and will not
be repeated here. The process of chemokine receptor modula-
tion on blood DCs and their precursors drives inﬂammatory
inﬂux into tissues. Once in the tissues, DCs also possess the
capability to reverse direction, cross the endothelial barrier, and
redistribute into blood circulation (Muller and Randolph, 1999;
Sozzani et al., 1999; Gordon and Taylor, 2005); however, direct
evidence of this reverse transmigration phenomenon is scarce.
Notably, CD16+ inﬂammatory monocytes have been shown to
enter the circulation from tissues in one study (Randolph et al.,
2002) and human MoDCs were able to reverse transmigrate
through human umbilical vein endothelial cells in vitro (D’Amico
et al., 1998). The endothelium plays a principal role as a bar-
rier to inﬂammatory inﬁltration from the vasculature, but also
facilitates DC transmigration particularly in response to inﬂam-
matory signals (Weis et al., 2002) and hypoxia (Schioppa et al.,
2003; Mancino et al., 2008). During infection, it is hypothesized
that transmigration contributes to the pathophysiological func-
tion called pathogen-trafﬁcking, whereby DCs carry microbes
from peripheral tissues into peripheral blood to distant sites,
thus contributing to inﬂammatory diseases, such as cardiovas-
cular disease (CVD; Ross, 1999; Niessner and Weyand, 2010;
Zeituni et al., 2010a) and arthritis (Thomas et al., 1999;Wang et al.,
2006).
NORMAL mDC FUNCTION: TISSUE vs. BLOOD
The role of DCs in immunity can also be subdivided based on
the predominant anatomical compartment in which they are
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found. Lymphoid resident DCs are non-migrating DCs that nor-
mally reside in the thymus and spleen, where they collect and
present antigen (Kabashima et al., 2005). These include tissue res-
ident DCs, namely Langerhans cells and interstitial DCs (intDC),
which have relatively long lifespans. This allows them to sur-
vey their local environment for danger signals or apoptotic host
debris. DCs actively clear away debris, take up and process anti-
gens, or alternatively, promote host tolerance. However, nearly
half of the DCs found in these tissues are not typical lymphoid
resident DCs, but consist of the classical migratory DC sub-
sets. The proper danger signals must be present to stimulate
DC maturation that allows DCs to respond to chemokine gra-
dients originating in peripheral lymph nodes (Luther et al., 2002).
This tightly regulated system allows stratiﬁcation of DC functions
according to anatomic site, thereby mitigating peripheral antigen
presentation, while favoring antigen-speciﬁc immune responses
at SLOs (Dieu et al., 1998; Balázs et al., 2002). While lymphoid
resident DCs are generally immature and actively take up anti-
gen, the classical migrating DCs have already matured and lost
antigen uptake capabilities by the time they reach the lymph
tissues.
As stated earlier, the predominant functions of bloodmDCs are
poorly understood. Immature blood DCs and monocytes tend to
have similar functions, but can drive a different scale of response
whenmatured. Peripheral bloodmDCs are differentially regulated
by the cytokinemilieu, which leads to alterations in surface expres-
sion of major histocompatibility complex class II (MHC-II) and
accessory molecules (Kohrgruber et al., 1999). Hence, these circu-
lating cells appear capable of processing antigen and stimulating
adaptive immunity, but this can be manipulated by their envi-
ronment (Thomas and Lipsky, 1994; Ito et al., 2001). It is widely
speculated that they may migrate in and out of tissues to replenish
tissue resident DCs (Ito et al., 1999; Varol et al., 2007; Merad and
Manz, 2009), but they also appear to have an active role in clear-
ance of bacteremia (Fanger et al., 1996; Balázs et al., 2002; Carrion
et al., 2012).
ACCESSORY MOLECULES: COSTIMULATORY AND
CO-INHIBITORY
In addition to DC number and location, the expression of acces-
sory molecules must be considered, as DCs must strike a balance
between promoting immunity and immune tolerance. They are
able to guide and direct the effector functions of T cells toward
immunogenic CD4+ T helper cells and cytotoxic CD8+ T cells
or toward tolerogenic regulatory T cells (Tregs; Bakdash et al.,
2013; Hubo et al., 2013). This directorial function depends on
three major signals that govern the cross talk between antigen-
presenting DCs and responding T cells. Signal 1 consists of
processed antigen peptide presented in the context of MHC com-
plexes to the speciﬁc T cell receptors (TCRs). Signal 2 consists of
upregulation of costimulatory/coinhibitory molecules for binding
to their respective receptors on T cells. Understanding the compo-
nents of costimulation/coinhibition mechanism is highly crucial
for elucidation and interpretation of immune responses and is
discussed further here (Bakdash et al., 2013). Signal 3 consists of
the proper repertoire of secreted cytokines, providing the ﬁnal
directions to the emerging T cells.
The B7 family of costimulatory molecules (CD80/CD86) are
the best deﬁned, and perhaps, most biologically signiﬁcant cos-
timulatory molecules involved in T cell activation. Interaction
between CD80 (B7.1) and CD86 (B7.2) on DCs (as well as on
macrophages and B cells) and their binding partner CD28 on
T cells (mainly on CD4+ T cells and some with less frequency
on CD8+ T cells) initiates the B7 costimulatory pathway. This
occurs through tyrosine phosphorylation and activation of the
PI3K/AKT, which, along with TCR signaling, promotes IL-2 gene
expression and cellular proliferation. This activation also occurs
simultaneously with the upregulation of anti-apoptotic genes. The
B7/CD28 costimulatory reaction not only initiates the activation
and proliferation of effector T cells, but also negatively affects the
tolerogenic capabilities of DCs and thereby reduces the induction
and activation of Tregs. Interestingly, it is well demonstrated that
activation of T cells through costimulatory molecules can be con-
tained by a negative feedback controlling system. This involves
polarization of CTLA-4 on activated T cells. CTLA-4 can compete
with CD28 costimulatory molecule to bind B7 ligands on DCs
with higher afﬁnity, resulting in suppression of effector T cells and
reduction in inﬂammatory responses (Bour-Jordan et al., 2011;
Hubo et al., 2013).
The other major member of B7 costimulatory family is the
ICOS (CD278)/ICOS-L (CD275) interaction. The ICOS/ICOS-L
pathway is a crucial player in T cell-dependent antibody response
to the antigens. Interestingly, some studies have shown co-
inhibitory functions for the ICOS/ICOS-L pathway involving
the production of anti-inﬂammatory cytokines, IL-10 and IL-
4, as well as induction of Tregs. This assigns a novel potential
immunotherapeutic role for ICOS/ICOS-L pathway in the treat-
ment of autoimmune diseases (Bakdash et al., 2013; Hubo et al.,
2013).
On the inhibitory side, the two ligands of programed death 1
(PD-1), PD-L1 and PD-L2, have emerged as crucial co-inhibitory
molecules. PD-L1 and PD-L2 initiate pathways for immune tol-
erance and modulation of T cell responses. Interaction of PD-1
with PD-L1 and PD-L2 can effectively suppress T cell responses
and lead to induction of Tregs. Stimulants, such as endotoxins
(LPS) or other immunostimulatory signals like CD40, may result
in PD-L1 signaling and immunosuppression. Unlike PD-L1, PD-
L2 is exclusively expressed by antigen-presenting cells (APCs; e.g.,
dendritic cells,macrophages). Altogether, the PD-1 pathway is one
of the major mechanisms responsible for the establishment of a
tolerogenic microenvironment, which can play an important role
as a therapeutic target in treatment of autoimmune and inﬂamma-
tory diseases (Bour-Jordan et al., 2011; Riella et al., 2012; Bakdash
et al., 2013; Hubo et al., 2013).
The CD40/CD40-L pathway is particularly inﬂuential in T cell
differentiation and sensitization. CD40-L, a member of the tumor
necrosis factor (TNF) superfamily, is presentedon activatedT cells.
This pathway can function in a dichotomous fashion, promoting
immunity or inducing tolerance, depending on the nature of the
cytokines and other factors in the microenvironment. OX40-L,
which is presentedonAPCs, has similar dual and complex function
asCD40-Lwhen reactswithCD40 (Hubo et al., 2013). Collectively,
the function of costimulatory/co-inhibitory pathways on DCs is
pivotal for immunity or tolerance.
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LINKS BETWEEN CHRONIC INFECTIONS AND mDC
FLUCTUATIONS
Low-grade chronic infections are detrimental to host health as
they routinely cause inﬂammatory ﬂare-ups, leading to host tissue
destruction. Implicit in this argument is that immune function
is impaired in the process, allowing pathogen persistence. For
productive immune responses, mDC must function to strongly
stimulate and polarize the innate and adaptive branches of immu-
nity. As mDCs are not efﬁcient killers of microorganisms in their
own right (Palucka and Banchereau, 2002; Geijtenbeek et al., 2003;
Macpherson and Uhr, 2004), they may provide a protective niche
for pathogens. One of the key events in many infections that
have been linked with systemic illness is pathogen dissemination
(Kelsall and Leon, 2005; Finlay and McFadden, 2006; Caws et al.,
2008; Brandtzaeg, 2009; Hayashi et al., 2010). This is explored
in Table 1. As a result of uptake and survival within mDCs,
pathogens consequently gain access to a highlymigratory“vehicle”
for dissemination.
As shown in Table 1, there are common the themes in the abil-
ity of chronic and acute pathogens to cause alterations in relative
mDC number and the ability to disseminate within mDCs. There
can be a localized inﬂammatory response, commensurate with
Table 1 | Association of shifts in blood dendritic cell numbers with inflammatory/infectious diseases.
Disease (pathogen) Immune function of mDCs
during infection
Changes to mDC
levels
Phenotype
markers
used
Pathogen
dissemination
Reference
Chronic
periodontitis
(P. gingivalis, others)
Intracellular bacterial
survival; lack of DC
maturation and immune
signaling, aberrant migration
Increased blood
mDC
CD1c+,
DC-
SIGN+,
CD19−
Yes Carrion (Carrion et al., 2012), Cutler (Cutler
and Jotwani, 2004; Cutler andTeng, 2007),
Miles (Miles et al., 2013a,b)
HIV Trans-infection of T cells,
HMGB1 promotes
dissemination and latency
Decreased blood
mDC; increased
shortly after ART
HLA-DR+,
CD11c+,
CD123−
Yes Chehimi (Chehimi et al., 2002), Engering
(Engering et al., 2002), Feldman (Feldman
et al., 2001), Gougeon (Gougeon et al.,
2012), Grassi (Grassi et al., 1999)
Gastrointestinal
inﬂammation (H.
pylori, others)
Increased IL-17 secretion and
Treg stimulation, localized
inﬂammation
Increased
mucosal mDCs
HLA-DR+,
CD11c+
Yes Baumgart (Baumgart et al., 2005), Vuckovic
(Vuckovic et al., 2001), Xavier (Xavier and
Podolsky, 2007)
Pneumonia (C.
pneumonias)
Matured, antigen
presenting, Th-2-inducing
immunity
Relatively
unchanged
HLA-DR+,
CD11C+
Yes Ojcius (Ojcius et al., 1998), Wittkop
(Wittkop et al., 2006), Bobryshev
(Bobryshev et al., 2004)
Tuberculosis
(M. tuberculosis)
Promote HIV trans-infection,
systemic dissemination from
granulomas in both acute
and chronic stages, impaired
Ag-presentation
n/a HLA-DR+,
CD11c+,
CD123−
Yes Chackerian (Chackerian et al., 2002),
Gringhuis (Gringhuis et al., 2009), Lichtner
(Lichtner et al., 2006), Tailleux (Tailleux et al.,
2003), Wolf (Wolf et al., 2007)
Diabetes mellitus Activation of autoreactive T
cells, autoimmunity, low
accessory molecules
Increased blood
mDCs
CD11c+ n/a Lee (Lee et al., 2011), Lo (Lo and
Clare-Salzler, 2006), Surendar (Surendar
et al., 2012)
Asthma and
allergies
Promote inﬂammation,
recruit mast cells,
eosinophils, etc.,
phagocytose allergens
Increased blood
and mucosal
mDCs
HLA-DR+,
CD11c+
n/a Idzko (Idzko et al., 2007), Lambrecht
(Lambrecht and Hammad, 2003),
Parameswaran (Parameswaran et al.,
2004), Spears (Spears et al., 2011), Upham
(Upham et al., 2002)
Chronic hepatitis
C virus (HCV)
Niche for viral replication,
normal IFN-α production,
Th-17 bias
Increased/
decreased blood
mDCs
HLA-DR+,
CD11C+
Yes Fang (Fang et al., 2013), Goutagny
(Goutagny et al., 2003), Longman
(Longman et al., 2005), Musilli (Musilli et al.,
2011),Wertheimer (Wertheimer et al., 2004)
Langerhans cell
histiocytosis (LCH)
DC recruitment via
hematopoietins
Increased blood
mDCs
HLA-DR+,
CD11c+
Yes Abla (Abla et al., 2010), Laman (Laman
et al., 2003), Rolland (Rolland et al., 2005)
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pathogen dissemination by non-stimulatory mDCs (i.e., imma-
ture mDCs), as seen with diseases such as chronic periodontitis
(CP), gastritis, asthma, and tuberculosis.
EXPANSION OF mDCs DURING CHRONIC PERIODONTITIS
A recent clinical study by our group (Carrion et al., 2012) showed
that CD1c+DC-SIGN+ mDCs were expanded in the periph-
eral blood of subjects with CP. This rise in mDC numbers was
expanded further when the CP subjects also had acute coronary
syndrome, a form of CVD. This was not due to an overall increase
in total peripheral blood mononuclear cells (PBMCs), nor was it
due to a rise in DC-poietins that would otherwise account for the
increased mDCs in circulation. The circulating mDCs were shown
to carry the oral pathogen Porphyromonas gingivalis, along with a
diverse microbiome. Moreover, DC-SIGN+ mDCs shown to con-
tain P. gingivalis were identiﬁedwithin the coronary artery plaques
in situ. As P. gingivalis targets DC-SIGN for entry into mDCs via
its glycoprotein ﬁmbriae, mfa-1 (Zeituni et al., 2009, 2010b), this
was deemed to have particular signiﬁcance to the pathophysiology
of both CP and CVD. CP and CVD have been linked epidemiolog-
ically, but the mechanisms involved in this association are unclear
(Dietrich et al., 2013). The results of our clinical study (reviewed
in Zeituni et al., 2010a) and two follow-up studies indicate that the
microbial carriage state of mDCs and their progenitors monocytes
activates DC differentiation (Miles et al., 2013a) and promotes
trafﬁcking of these infected mDCs to sites of neovascularization
(Miles et al., 2013b) such as diseased coronary arteries, thereby
increasing the CVD risk associated with CP.
As with other diseases highlighted in Table 1, the elevated
mDCs in CP lack proper accessory molecule expression for driv-
ing robust adaptive immune responses. Hence, it appears that
while blood mDCs serve an important clearance function for bac-
teremia, when facedwith amicrobe that targets DC-SIGNor other
immunoregulatory routes, this clearancemaybedetrimental to the
host (Zeituni et al., 2009).
CORRELATION OF MICROBIAL AND NON-MICROBIAL
FACTORS WITH FLUCTUATIONS IN mDC NUMBERS
Both non-microbial and microbial stimuli can induce ﬂuctuations
in bloodmDCnumbers, ostensibly throughdifferentmechanisms.
Inﬂammatory asthma is an example of a non-microbial disease
that elicits elevations in certain peripheral blood DC subpop-
ulations. This elevation in DCs is believed to be important in
the development and maintenance of symptoms (Upham et al.,
2002; Parameswaran et al., 2004; Spears et al., 2011). Moreover,
the activation of DCs is an important mediator of continued
inﬂammation in asthmatic patients (Lambrecht and Hammad,
2003; Idzko et al., 2007). Another non-microbial disease, Langer-
hans cell histiocytosis (LCH), results in increased circulating mDC
levels commensurate with a rise in hematopoietic cytokines (Rol-
land et al., 2005). The cause of this rise in blood mDCs is unclear,
but it has been speculated that this imbalance may replenish tis-
sue DCs that have migrated to lymph nodes, or represents reverse
transmigration of DCs into blood circulation (Laman et al., 2003).
Prominent among the microbial stimuli is M. tuberculosis, a par-
ticularly effective pathogen by virtue of its ability to infect mDCs
at a high rate and to obtund antigen presentation (Wolf et al.,
2007). It also expands the circulating mDC pool with mDCs
that lack IFN-α production necessary for effective immune func-
tion (Lichtner et al., 2006). The circulating mDCs associated with
M. tuberculosis infection also drive pathogen dissemination prior
to the development of a productive T cell response (Chackerian
et al., 2002). Pneumonia, induced by pathogenic species such as
Chlamydia pneumoniae, is associated with increased circulating
mDCs that disseminate the pathogen to various sites in the host
(Ojcius et al., 1998). The mDCs generated during C. pneumoniae
infections in one report are functionally suppressive. The mDCs
disseminate the pathogen and drive immunosuppressive T cell
stimulation (Wittkop et al., 2006). Viruses (e.g., hepatitis C virus,
HCV) can also infect mDCs and expand suppressive immune
responses, typically through Th-17 response (Fang et al., 2013).
HIV infection is known to cause immunosuppressive responses
such as impaired effector T cell function, cell death, and Treg
induction during progression to chronic disease. HIV tropic virus
can infect mDCs and subsequently trans-infect T cells (Enger-
ing et al., 2002). The blood mDC responses in patients with
inﬂammatory bowel disease (IBD) vary widely, from reports of
no change in mDC numbers to elevated numbers. Regardless,
the mDCs are typically activated and hyperstimulatory (Vuck-
ovic et al., 2001; Baumgart et al., 2005, 2009; Xavier and Podolsky,
2007).
During acute infections, elevations in non-functional or
immunosuppressive mDCs is a common occurrence. For exam-
ple, infections with P. falciparum, dengue virus, or inﬂuenza
virus typically trigger a rise in circulating blood mDCs which
may favor pathogen dissemination and chronic inﬂammation
(Aldridge et al., 2009; Cao et al., 2012; Ibitokou et al., 2012; Tor-
res et al., 2013). During sepsis and shock, rapid elevations of
mDCsoccur throughdifferentiation of precursors in blood (Faivre
et al., 2007, 2012). Conﬂicting reports of sustained decreases
in circulating mDCs in septic shock are also evident (Inoue
et al., 2010; Grimaldi et al., 2011). Other conﬂicting reports are
also evident. During HIV infection, mDCs numbers generally
decrease in the blood circulation (Grassi et al., 1999; Feldman
et al., 2001), but are increased in HIV patients after treatment
with highly active antiretroviral therapy (HAART; Chehimi et al.,
2002). In addition, the blood mDC levels during HCV infec-
tion and chronic liver disease are somewhat controversial, with
both reports of decreases (Goutagny et al., 2003; Longman et al.,
2005) or no changes (Wertheimer et al., 2004). As DC-SIGN is
used as a ligand for HIV (Kwon et al., 2002; Gringhuis et al.,
2009) and is one of many targets for HCV entry (Lozach et al.,
2003), mDC ligation via DC-SIGN and the resulting intracellu-
lar routing could explain some irregularities of subsequent DC
function.
A ROLE FOR mDC FLUCTUATION AND INFLAMMATORY
RESPONSE IN DIABETES
The importance of mDC function is also highlighted in autoim-
mune diabetes, in which mDC populations are increased, and
drive activation of autoreactive T cells (Lo and Clare-Salzler,
2006). This supports our underlying common theme that dis-
eases of microbial and non-microbial origin have in common a
dysregulation in mDC homeostasis, resulting in dissemination
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of pathogens, allergens, and/or self-antigens. In each instance,
the dysfunction in mDCs as a result favors pathogen/allergen
persistence and prevents effective antigen-speciﬁc immunity and
clearance.
Both autoimmune and type-II diabetes, widespread diseases
that are tied very closely with immune function, have been
linked with CP and mDC dysfunction. Circulating mDC popu-
lations are increased in both type-II diabetic patients and obese
diabetic patients (Musilli et al., 2011; Chmelar et al., 2013). Sev-
eral oral pathogens are elevated during non-insulin-dependent
diabetes mellitus and may play a role in progression of both dia-
betes and periodontal disease severity (Yuan et al., 2001). The
development of diabetes mellitus contributes to the exacerbation
of periodontal disease and ligature-induced periodontal disease
in turn has been linked to decreased insulin sensitivity in rats
(Colombo et al., 2012). In contrast, diabetes in mice was found
to be unchanged upon induction of experimental periodontitis
by P. gingivalis in vivo (Li et al., 2013). Evidence is beginning to
point toward a role for periodontal inﬂammation in development
of type-II diabetes and that inﬂammatory mediators produced
by monocyte/macrophages during immune responses to peri-
odontitis may lead to insulin resistance (Nishimura et al., 2003).
Hence, it is now believed that these diseases form a bidirectional
relationship.
The use of animal models has also demonstrated that peri-
odontal symptoms upon P. gingivalis infection are worsened with
diabetes (Ensminger et al., 2008), but the mechanisms are unclear.
Further, TLR-2 activation and signaling, which are pronounced
during CP and which are crucial for mDC function against P.
gingivalis (Asai et al., 2007; Kanaya et al., 2009), have been found
to play a role in autoimmune diabetes progression (Kim et al.,
2011; Lee et al., 2011). Levels of DC-poietins, such as GM-CSF,
were observed to be elevated in diabetes patients, which correlated
to increased numbers and activation state of mDCs in periph-
eral blood. Interestingly, normal levels of GM-CSF and mDCs
were restored upon combination therapy with insulin and oral
hypoglycemic agents (Surendar et al., 2012). This suggests that
with proper diagnosis, blood mDC levels may be restored and
symptoms of inﬂammatory autoimmune diabetes averted.
DENDRITIC CELL FREQUENCY AS PREDICTIVE MEDICINE
The damage to the host caused by chronic diseases are often irre-
versible; thus the timing of risk assessment is crucial to prevention
of adverse health effects. For example, the diagnosis of LCH can
be missed or delayed until symptoms and systemic dysfunction
became widespread (Abla et al., 2010). In IBD, circulating and tis-
sue mDCs are highly active and display an easily detectable mature
phenotype (Hart et al., 2005). Enumeration and characterization
of accessory molecules on blood mDCs could provide a minimally
invasive and accurate tool to diagnose disease risk and prevent
late-stage symptoms of chronic inﬂammatory disease. Attempts
to address the links between microbial organisms and systemic
disease have been made recently through the use of large clinical
trials. Speciﬁcally, patients with cardiovascular illness have been
treated with systemic antibiotics to ascertain if elimination of bac-
teremic and disseminating pathogens could improve clinical out-
comes. These treatments have been largely unsuccessful (Andraws
et al., 2005; Gurﬁnkel and Lernoud, 2006), but it is unclear
if these antibiotics effectively eliminate intracellular pathogens.
Hence, continued improvements to assess mDC levels and intra-
cellular antibiotic levels are necessary to fully assess patient
outcomes.
In addition, the frequency and subtype of mDCs in blood may
shed light on the development of autoimmune disease before
symptoms become pronounced. Increased blood mDC differ-
entiation occurs in autoimmune systemic lupus erythematosus
(SLE) and could potentially be used to determine and limit the
severity of autoreactive B and T lymphocyte function (Gill et al.,
2002). Treatment of DCs with vitamin D receptor ligands has been
found to inhibit their alloreactive T cell stimulatory capacity and
enhances their Treg activation, which can resolve autoimmune
disease (Grifﬁn et al., 2001; Adorini, 2003; Adorini et al., 2004).
Recent work in our lab and others show that there may be a
window of opportunity to assess blood mDC populations before
the acceleration of systemic inﬂammatory diseases. It appears that
the low-grade infections of chronic and acute nature highlighted
here, elicit disruption of blood DC homeostasis. This disruption
of DC homeostasis can contribute to the early or late progres-
sion of inﬂammatory disease. DC populations are not detected by
typical complete blood counts in clinical laboratories. When they
are, it is because severe manifestations of inﬂammatory disease
are present. At this stage, the window of opportunity is lost, as
mDCs have already inﬁltrated tissues, coinciding with a decrease
of circulating mDCs. Therefore, monitoring of mDC levels and
their activation state in blood, especially during chronic infection,
should be further investigated as a predictive tool for additional
disease and chronic inﬂammatory risk.
PATHOGEN-DRIVEN DENDRITIC CELL EXPANSION AND
DISSEMINATION
The oral mucosal infection CP is characterized by accumulation
of a pathogenic bioﬁlm on the tooth surface, which eventually
leads to a high degree of tissue and bone loss caused by the host
response (Casarin et al., 2010; Darveau, 2010). Certain micro-
bial species, notably among them the anaerobic Gram-negative
bacterium P. gingivalis (Byrne et al., 2009; Hajishengallis et al.,
2012), produce destructive proteolytic enzymes and lead to spikes
in inﬂammatory responses (Hajishengallis, 2009). Among these
inﬂammatory responses is the inﬁltration and activation of mDCs
(Cutler and Jotwani, 2004, 2006; Cutler and Teng, 2007). These
mDCs express the C-type lectin and pattern recognition recep-
tor (PRR) DC-SIGN, which is used as an invasin by a broad
range of pathogenic organisms (Lozach et al., 2003; Tailleux et al.,
2003; Gringhuis et al., 2009; Mesman et al., 2012). In the case of
P. gingivalis, a ﬁmbrial adhesin is expressed, the 67-kDa minor
ﬁmbriae (mfa-1), which is glycosylated and targets DC-SIGN for
entry into mDCs (Zeituni et al., 2010b). This interaction has also
been shown to skewmDC function away frommaturation, leading
to low accessory molecule expression and an immunosuppressive
cytokine production (Zeituni et al., 2009).
NON-CANONICAL PATHOGEN-DIFFERENTIATED DCs
More recent in vitro ﬁndings in our lab show that P. gingi-
valis, through its interaction with DC-SIGN, rapidly induces
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differentiation of MoDCs from monocyte progenitors. These
DCs, which we termed pathogen-differentiated DCs (PDDCs),
are CD1c+DC-SIGN+CD14−, but immature in phenotype and
function unless forced to mature with inﬂammatory cocktail. It
is believed that intracellular routing through DC-SIGN allows
for pathogen survival in passive compartments that avoid lyso-
somal fusion and is a current line of investigation by our
group. In addition, this interaction further dysregulates DC
homeostasis by driving an aberrant chemokine receptor pro-
ﬁle. As highlighted in Figure 1, this has implications for both
pathogen dissemination and immune subversion. Bacteremia
is frequent and transient during CP (Parahitiyawa et al., 2009;
Pérez-Chaparro et al., 2009; Morozumi et al., 2010), which could
drive sustained blood mDC increased through generation of
non-canonical PDDCs. These PDDCs would provide a protec-
tive niche for the pathogen, obviating antigen processing and
presentation required for effective immune response. Finally,
these PDDCs display poor lymphoid-homing capabilities (Miles
et al., 2013b) which prevents them from stimulating effector cell
responses. Instead these PDDCs circulate through bloodstream
and inﬁltrate distant sites, with the arterial wall depicted, which
leads to localized inﬂammation and negatively effects systemic
health.
BLOOD mDCs AS CARRIERS OF INFECTION
Other pathogens can inﬂuence DC differentiation and activa-
tion, while occupying a protective niche within DCs to escape
immune clearance. Mucosal pathogens HCV (Goutagny et al.,
2003), C. pneumoniae (Wittkop et al., 2006), HIV (Gougeon et al.,
2012), and M. tuberculosis (Chackerian et al., 2002), among oth-
ers, survive and replicate within DCs. Interestingly, many of these
pathogens are found to be disseminated to distant sites within the
host and thought to have a role in inﬂammatory disease (Bobry-
shev et al., 2004). Evidence suggests that these mucosal pathogens
are carried to distant sites within DCs, serving as vehicles of dis-
semination (Bobryshev, 2005; Bosio, 2010; Niessner and Weyand,
2010).
POTENTIAL ROLE FOR NOVEL DC DIFFERENTIATION IN
IMMUNOTHERAPY
Due to their high degree of plasticity, mobility, and ability when
mature to stimulate a robust speciﬁc immune response,DC subsets
are attractive targets for immunotherapy and vaccine develop-
ment (Fong and Engleman, 2000; Ueno et al., 2010). Different
DC subsets display different recognition receptors and produce
different cytokine proﬁles, which can lead to ﬁne tuning of spe-
ciﬁc desired immunological outcomes (Klechevsky et al., 2009).
FIGURE 1 | Proposed mechanisms of induction of immunosuppressive
pathogen-differentiated dendritic cells (PDDCs). Low-grade bacteremia,
such as in chronic periodontitis, stimulate monocyte to dendritic cell
differentiation, resulting in immature non-canonical PDDCs. These long-lived
PDDCs contain viable bacteria and do not home through the lymphatics to
secondary lymphoid organs where they would be able to prime effector T
cells. Rather, infected PDDCs are able to circulate through the blood and
trafﬁc to various inﬂammatory sites, such as atherosclerotic plaques. After
migrating to these sites, they further the extent of local inﬂammation and
adversely contribute to systemic illness.
www.frontiersin.org January 2014 | Volume 5 | Article 6 | 7
“fmicb-05-00006” — 2014/1/23 — 16:56 — page 8 — #8
Miles et al. Blood dendritic cells in predictive medicine
The use of DC vaccines also provides an opportunity to stimu-
late not only humoral immunity, but cellular immunity as well
(Palucka et al., 2010). This is crucial to developing a vaccine cur-
rently lacking, for intracellular pathogens such as HIV, HCV, and
tuberculosis. DC vaccines are also attractive as cancer therapies.
The use of DCs can allow for speciﬁc immunity against subtle
differences in host cells while preventing widespread inﬂamma-
tion and damage seen with chemotherapeutic agents. DC-based
immunotherapy in clinical trials for cancer is a particularly exciting
ﬁeld (reviewed in Vacchelli et al., 2013). Various challenges in this
regard include poor immunogenicity of target cells, insufﬁcient
function of transplanted immune cells, low immune stimula-
tion by in vitro generated DCs or short lived nature of these
DCs (Bronte et al., 1997; Wang et al., 1998; Rosenberg et al.,
2004).
In Figure 2, we propose a ﬂow diagram for the development of
a DC vaccine that would take advantage of PDDCs and promote
a tailored, speciﬁc immune outcome. PDDCs could be gener-
ated with various bacterial analogs, such as was shown with P.
gingivalis mfa-1. These PDDCs are longer lived in vitro than con-
ventional MoDCs and require additional maturation (Miles et al.,
2013a). Large populations of PDDCs could be generated from
abundant monocyte precursors that display the desired immuno-
genicity and T helper cell stimulating ability. These PDDCs can
then be transferred back to patients and either drive antigen-
speciﬁc immunity or prevent inﬂammation and autoimmunity
through immune suppression. By using the various subsets of
PDDCs, immune responses can be tailored to produce stimula-
tory or tolerogenic effector responses. Therefore, it is plausible that
DC immunotherapy could potential target autoimmune diseases.
Evidence already suggests thatmDCs can trigger immunosuppres-
sive responses to reduce diabetesmellitus symptoms (Clare-Salzler
et al., 1992; Tarbell et al., 2004).
CONCLUDING REMARKS
The frequency and phenotype of blood mDCs may provide a
diagnostic tool for assessing patient risk for inﬂammatory dis-
ease. To this should be added an assessment of the transcriptome
and microbiome of blood mDCs. Differences among subjects
in their mDC responsiveness to antigen challenge and the co-
stimulatory, co-inhibitory phenotype of said mDCs may be
particularly amenable to the personalized medicine paradigm.
This can lead to early diagnosis before the most extreme of symp-
toms are manifest and thus improving the efﬁcacy of treatment.
The ability of DCs to shape T cell immunity also makes them very
attractive targets for clinical therapies targeting cancer, autoim-
mune disease, and chronic infections. Speciﬁcally, subsets of
DCs that can drive antigen-speciﬁc tolerance are highly desirable
for clinical vaccination and prevention of autoimmunity. This
antigen-speciﬁc tolerance has potential to deliver very produc-
tive and speciﬁc responses while limiting collateral damage from
immune activation.
FIGURE 2 | Proposed therapeutic use of pathogen-differentiated dendritic cells (PDDCs). In lieu of using traditional GM-CSF/IL-4-cultured
monocyte-derived DCs for immunotherapy, monocytes are treated with bacterial analogs to induce iTreg- or Th-17-inducing PDDCs, and PDDCs loaded along
with speciﬁc antigen, depending on the disease to be treated.
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